Accelerated Approval Program
30 Years On: Insights and Experiences

March 11, 2022 | 1-4 PM eastern

 

InfographicThe Accelerated Approval Pathway was created by Congress to allow patients with a serious or life-threatening disease earlier access to a potentially important treatment. At this virtual public meeting we explored the insights and lessons learned in the 30 years since its inception.

View the recorded event and read meeting materials below. 

 

 

 

 

Download infographic

 

TranscriptRead the transcript deckView the slide deck

Agenda

Moderated by Susan C. Winckler, RPh, Esq. 
CEO, Reagan-Udall Foundation for the FDA

1 PM Welcome & Opening Remarks
1:05

Accelerated Approval 1992-2022

  • Accelerated Approval 30 Years On: Lessons and Next Steps
    Jacqueline Corrigan-Curay
    , JD, MD, Principal Deputy Center Director, Center for Drug Evaluation and Research, FDA
  • Failure or Success, Results are Essential
    Kevin Fain,
    JD, MPH, DrPH, Senior Policy Advisor, Office of New Drug Policy, Center for Drug Evaluation and Research, FDA
  • Accelerated Approval in Oncology: 1992-2022
    Gautam Mehta, MD, Clinical Reviewer and Medical Officer, Office of New Drugs, Center for Drug Evaluation and Research, FDA
2:05

Patient Perspective Panel
Moderated by Susan C. Winckler, RPh, Esq., CEO, Reagan-Udall Foundation for the FDA

  • Alberto Rubio, MBA
  • Teonna Woolford
  • Navdeep Singh, PhD
  • Katherine Couvillon
3:00

Fireside Chat Sharing Patient Advocacy, Provider, Industry, and Payer Perspectives
Moderated by Susan C. Winckler, RPh, Esq., CEO, Reagan-Udall Foundation for the FDA

  • Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer, American Society of Clinical Oncology
  • Kay Holcombe, MS, Board Chair, National Organization for Rare Disorders
  • Michelle McMurry-Heath, MD, PhD, President & CEO, BIO
  • Michael Sherman, MD, MBA, Chief Medical Officer, Point 32 Health
3:55 Closing Remarks/Adjourn

Speaker & Moderator Biographies